SELUX DIAGNOSTICS
SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA.
SELUX DIAGNOSTICS
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2014-01-01
Address:
Charlestown, Massachusetts, United States
Country:
United States
Website Url:
http://www.seluxdx.com
Total Employee:
11+
Status:
Active
Contact:
617-945-9383
Email Addresses:
[email protected]
Total Funding:
172.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Exai Bio
Exai Bio is a next-generation Orphan non-coding RNAs and AI based liquid biospy company.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Juno Diagnostics
Juno Diagnostics is a healthcare technology company developing the next generation cell-free DNA-based noninvasive prenatal test solutions.
Current Advisors List
Current Employees Featured
Founder
Investors List
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - SeLux Diagnostics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - SeLux Diagnostics
RA Capital Management
RA Capital Management investment in Series C - SeLux Diagnostics
Schooner Capital
Schooner Capital investment in Series C - SeLux Diagnostics
Sands Capital Ventures
Sands Capital Ventures investment in Series C - SeLux Diagnostics
Northpond Ventures
Northpond Ventures investment in Series C - SeLux Diagnostics
National Institutes of Health
National Institutes of Health investment in Grant - SeLux Diagnostics
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - SeLux Diagnostics
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - SeLux Diagnostics
Northpond Ventures
Northpond Ventures investment in Series B - SeLux Diagnostics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-16 | Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer |
Official Site Inspections
http://www.seluxdx.com Semrush global rank: 5.6 M Semrush visits lastest month: 1.51 K
- Host name: 54.0.153.160.host.secureserver.net
- IP address: 160.153.0.54
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "SeLux Diagnostics"
About Selux - Selux Diagnostics
Selux’s interdisciplinary team of expertise in microbiology, biochemistry, chemistry, engineering, software, and algorithm design is buttressed by distinguished experts in Clinical Microbiology, …See details»
SeLux Diagnostics - Crunchbase Company Profile
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. SeLux Diagnostics announced that it received an additional $48 million in funding.See details»
Meet the Team - Selux Diagnostics
Our network brings together the best and brightest to develop the groundbreaking NGP technology that can deliver personalized diagnostic information to optimize treatment when …See details»
Selux Diagnostics, Inc | LinkedIn
Selux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and …See details»
Selux Diagnostics Announces Additional $48 Million in Funding
Apr 1, 2024 This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only …See details»
Selux Diagnostics Announces Additional $48 Million in Funding
Apr 1, 2024 For more information on the Selux NGP System, visit www.seluxdx.com. Acknowledgment This platform has been supported in whole or in part with federal funds from …See details»
FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility …
Jan 19, 2023 In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for …See details»
Selux Diagnostics Receives $8.0 Million in Additional Funding to ...
The $8.0 million was received as part of the company's milestone-based BARDA contract, which is worth $60.8 million if all options are exercised.See details»
Selux Diagnostics Receives FDA Clearance on Their Gram
Apr 24, 2023 seluxdx.com . Selux 56 Roland Street , #106 Charlestown, MASSACHUSETTS 02129 . Contacts. Andrea LePain. [email protected] 617-894-1153 More Press …See details»
FDA Clears 'Selux NGP System' for Rapid Antibiotic ... - Newswire
Jan 19, 2023 seluxdx.com . Selux 56 Roland Street , #106 Charlestown, MASSACHUSETTS 02129 . Contacts. Andrea LePain. [email protected] 617-894-1153 More Press …See details»
Our Technology - Selux Diagnostics
Designed to outsmart bacteria. From the labs to the patients, we take our work personally. The Selux NGP System is a single-platform technology capable of addressing speed to result, …See details»
Selux Diagnostics Earns FDA Breakthrough Device Designation for …
Sep 28, 2021 Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation 'Phenotyping' (NGP) Platform for Positive Blood Culture and Sterile Body Fluid …See details»
Selux Diagnostics Receives $8.0 Million in Additional
Jul 12, 2022 Latest milestone brings the Selux Next-Generation Phenotyping (NGP) platform one step closer to impacting patient care with same-shift Antibiotic Susceptibility Testing (AST).See details»
Analyzer - Selux Diagnostics
86-panel capacity. The Selux Analyzer can run multiple samples at the same time. With its 86-panel capacity and random-access capabilities, the Selux Analyzer allows for fast, accurate …See details»
Selux Diagnostics Receives Additional $14.6 Million in BARDA …
Jun 8, 2021 Selux Diagnostics Receives Additional $14.6 Million in BARDA Funding After Successfully Completing First Clinical Trial Latest milestone validates the Selux NGP …See details»
Selux Diagnostics Announces Additional $48 Million in Funding
Apr 1, 2024 [email protected] 801-512-5044 . SOURCE: Selux Diagnostics. View the original press release on newswire.com.See details»
Startup Selux Diagnostics Details High-Throughput AST, MIC
Feb 7, 2019 With a recent scientific publication under its belt, the company hopes to compete in the space of rapid automated phenotypic AST. SeluxDx expects to begin clinical trials of its …See details»
Precision diagnostics for infectious diseases - Selux Diagnostics
Sheldon Campbell, MD, PhD, member of the CAP Checklists Committee, says of the new requirement (MIC.11385 Current Antimicrobial Susceptibility Test Interpretation Breakpoints) …See details»
News - Selux Diagnostics
Selux Receives FDA Clearance on Their Gram-Negative Panel June 16, 2023See details»